Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.76 |
| ▸ | FLT3 | P36888 | 5/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.76 |
| ▸ | MAOB | P27338 | 5/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.76 |
| ▸ | IP6K2 | Q9UHH9 | 4/20 | 0.76 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.76 |
| ▸ | HPGD | P15428 | 4/20 | 0.76 |
| ▸ | GABRP | O00591 | 4/20 | 0.76 |
| ▸ | GABRD | O14764 | 4/20 | 0.76 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.76 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.76 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12792657 | 0.88 | CCNC (0.76) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| SCHEMBL10026574 | 0.87 | POLH (0.74) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL5083245 | 0.86 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL19428 | 0.86 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL29351464 | 0.86 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| SCHEMBL20664434 | 0.86 | ADORA3 (1.00) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| SCHEMBL12636897 | 0.85 | CYP1B1 (0.81) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL1658882 | 0.85 | KMT2A (0.97) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL31168790 | 0.85 | KMT2A (0.97) | KMT2AMAPTMEN1CYP3A4FLT3 | |
| Apigenin SCHEMBL29448148 | 0.85 | KMT2A (0.97) | KMT2AMAPTMEN1CYP3A4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085383-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-03-29 | — | — | US | disclosed |
| US-9415034-B2 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2016-08-16 | — | — | US | disclosed |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | NAT DEFENSE MEDICAL CT (TW) | 2016-06-30 | — | — | US | disclosed |
| US-20160024527-A1 | Compositions and Methods for Enhancing Bioenergetic Status in Female Germ Cells | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-01-28 | — | — | US | disclosed |
| EP-2387712-B1 | NONINVASIVE MEASUREMENT OF FLAVONOID COMPOUNDS IN BIOLOGICAL TISSUE | SHARIFZADEH MOHSEN (US) | 2014-06-04 | — | — | EP | disclosed |
| US-8420141-B2 | Food coloring | PEPSICO, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2012118287-A2 | NOVEL COMPOUND ISOLATED FROM ALLIUM TUBEROSUM AND USE THEREOF AS ANTIVIRAL AGENT | KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP. (KR) | 2012-09-07 | — | — | WO | disclosed |
| US-8142829-B2 | Beverage composition and method of reducing degradation of monatin | PEPSICO, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-7880059-B2 | Production of proanthocyanidins to improve forage quality | THE SAMUEL ROBERTS NOBLE FOUNDATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100075005-A1 | Beverage composition and method of reducing degradation of monatin | PEPSICO, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090083874-A1 | PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY | THE SAMUEL ROBERTS NOBLE FOUNDATION | 2009-03-26 | — | — | US | disclosed |
| US-20090074708-A1 | Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL UNIVERSITY (TW) | 2009-03-19 | — | — | US | disclosed |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | LIU YAGUANG (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090083874-A1 | PRODUCTION OF PROANTHOCYANIDINS TO IMPROVE FORAGE QUALITY | QPCTL, FABP6, HHAT | KMT2A 2296/4885MAPT 2155/4885MEN1 2562/4885 |
| US-20040072790-A1 | Safe natural pharmaceutical composition for treating cancer | MATR3, HPN, HAMP | KMT2A 425/4885MAPT 392/4885MEN1 658/4885 |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | UGT2B7, UGT2B17, UGT1A10 | KMT2A 4826/4885MAPT 2113/4885MEN1 4841/4885 |
| US-20160024527-A1 | Compositions and Methods for Enhancing Bioenergetic Status in Female Germ Cells | PCK2, GSR, TFAM | KMT2A 2889/4885MAPT 4110/4885MEN1 4369/4885 |
| US-20180085383-A1 | SMALL MOLECULE CD38 INHIBITORS AND METHODS OF USING SAME | CD38, BCL6B, DNASE1L3 | KMT2A 1199/4885MAPT 3326/4885MEN1 3469/4885 |
| US-20090074708-A1 | Inhibitors and Enhancers of Uridine Diphosphate-Glucuronosyltransferase 2B (UGT2B) | UGT2B7, UGT2B17, UGT1A10 | KMT2A 4826/4885MAPT 2113/4885MEN1 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.